Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy by Satoh, Minoru et al.
Nephrol Dial Transplant (2008) 23: 3806–3813
doi: 10.1093/ndt/gfn357
Advance Access publication 2 July 2008
Original Article
Angiotensin II type 1 receptor blocker ameliorates uncoupled
endothelial nitric oxide synthase in rats with experimental
diabetic nephropathy
Minoru Satoh1,∗, Sohachi Fujimoto1,∗,S a y a k aA r a k a w a 1, Toyotaka Yada2, Tamehachi Namikoshi1,
Yoshisuke Haruna1, Hideyuki Horike1, Tamaki Sasaki1 and Naoki Kashihara1
1Division of Nephrology, Department of Internal Medicine and 2Department of Medical Engineering and Systems Cardiology,
Kawasaki Medical School, Kurashiki, Okayama, Japan
Abstract
BackgroundRecentstudiesshowedthatangiotensinIItype
1 receptor blocker (ARB) slows progression of chronic re-
nal disease in patients with type 2 diabetes, regardless of
changes in blood pressure. We showed that the imbalance
of nitric oxide (NO) and reactive oxygen species (ROS)
due to endothelial NO synthase (eNOS) uncoupling con-
tributed to renal dysfunction in the diabetic nephropathy.
The aim of this study was to determine the effects of ARB
on uncoupled eNOS in rat diabetic nephropathy.
Methods. Diabetes was induced in Sprague-Dawley rats
with streptozotocin (65 mg/ kg body weight). After 6
weeks, rats were divided into saline (DM; n = 11)
and ARB, losartan groups (DM+Los; n = 11). After
2-week treatment, glomerular ROS production was as-
sessed by 2 ,7 -dichlorofluorescin diacetate (DCFH-DA)-
derived chemiluminescence. Renal NO and ROS produc-
tion were imaged by confocal laser microscopy after renal
perfusion with DCFH-DA and diaminorhodamine-4M ace-
toxymethyl ester with L-arginine. The dimeric form of
eNOS was measured by low-temperature sodium do-
decyl sulfate–polyacrylamide gel electrophoresis. Serum
tetrahydrobiopterin (BH4) concentrations were determined
by high-performance liquid chromatography. Protein and
mRNA expression of GTP cyclohydrolase 1 (GTPCH1),
key enzyme of BH4 synthesis, were examined.
Results Losartan attenuated glomerular ROS production in
DM.AcceleratedROSproductionanddiminishedbioavail-
able NO caused by NOS uncoupling were noted in DM
glomeruli. Losartan reversed the decreased GTPCH1 and
decreased dimeric form of eNOS and glomerular NO pro-
duction by increased BH4 bioavailability.
Conclusions. ARB improved the NOS uncoupling in dia-
betic nephropathy by increasing BH4 bioavailability.
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Introduction
There is growing evidence that endothelial dysfunction,
which is often defined as a decrease in the bioavailability
of endothelial-derived nitric oxide (NO), is a critical patho-
logical state that could lead to vascular disease states such
as hypertension, atherosclerosis and diabetes. Because su-
peroxide rapidly scavenges NO within the endothelium, a
reduction in bioactive NO might occur despite the increase
in NO generation. Among many enzymatic systems that
are capable of producing superoxide, the NAD(P)H oxi-
dase and the uncoupled endothelial NO synthase (eNOS)
are the main sources of superoxide in vascular wall [1] in
diabetic patients. We also reported that in rat diabetic kid-
ney, NAD(P)H oxidase and uncoupled eNOS were major
sources of glomerular superoxide [2]. Accordingly, these
mechanisms are potential key targets for therapeutic inter-
ventions in endothelial dysfunction.
It was demonstrated that administration of angiotensin
II (Ang II) receptor blockers (ARBs) slows the progression
of diabetic nephropathy [3] and the development of pro-
teinuria [4] in patients with type 2 diabetes. This effect is
specific and independent of their blood pressure lowering
effect. Inhibition of the Ang II type 1 (AT1) receptor in
diabetic patients reverses endothelial dysfunction [5]. Fur-
thermore, long-term treatment with the ARB normalizes
the structure of subcutaneous small arteries of hypertensive
patients with non-insulin-dependent diabetes [6]. Thus, the
control of Ang II signalling by ARB could be potentially
effective in improving endothelial function in diabetes.
However, it is not clear whether ARB could improve eNOS
uncoupling in hyperglycaemia-induced diabetic nephropa-
thy. Accordingly, it was decided to examine whether short-
term blockade of the AT1 receptor using losartan would
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have favourable effects on uncoupled eNOS in the diabetic
glomeruli of rats with streptozotocin (STZ)-induced dia-
betes by lowering oxidative stress.
Subjects and methods
Experimental protocol and tissue preparation
The experimental protocol (No. 06-029) was approved in
advance by the Ethics Review Committee for Animal Ex-
perimentation of the Kawasaki Medical School (Kurashiki,
Japan). Male Sprague-Dawley rats (6–7 weeks old)
weighing 190 to 220 g were purchased from Charles River
Japan Inc. (Kanagawa, Japan). Diabetes was induced by a
single tail vein injection of STZ (65 mg/kg body weight;
Sigma-Aldrich Japan, Tokyo, Japan) diluted in a citrate
buffer, pH 4.5 [diabetes mellitus (DM); n = 22]. Age-
matched non-diabetic control rats (Cont; n = 22) were each
injected with an equal volume of citrate buffer. Six weeks
after induction of DM, 11 rats from each group were pro-
vided over a period of 2 weeks with drinking water contain-
ing losartan (Banyu Pharmaceutical, Japan; 30 mg/kg/day,
Cont+Los and DM+Los group). During the experimen-
tal period, body weight and blood glucose were measured
weekly in each rat. At 8 weeks after induction of DM, the
mean blood pressure was measured by the tail-cuff method,
and 24-h urine samples were obtained by using metabolic
cages. Albumin concentrations in 24-h urine samples were
measured by an ELISA kit (Exocell, Philadelphia, PA,
USA). Eight weeks after induction of DM, the rats were
anaesthetized with pentobarbital (50 mg/kg body weight)
and serum was isolated and assayed for creatinine. From
six rats in each group, the cortical tissue of the left kidney
was cut into small pieces and the glomeruli were isolated
by the mechanical graded sieving technique. The suspen-
sion of the glomeruli was then used for reactive oxygen
species (ROS) production assay and protein isolation. The
right kidney was used for immunohistochemistry. Five rats
in each group were used for the in situ detection of NO and
ROS.
Fluorescence spectrometric assay for production of ROS
in isolated glomeruli
Production of peroxides, including H2O2 and peroxynitrite,
was measured in isolated glomeruli using the 2 ,7 -
dichlorodihydrofluorescein-diacetate (DCFH-DA)method,
as previously described [7]. Isolated glomeruli from each
group were incubated in RPMI-1640 containing 0.5 mM
DCFH-DA (excitation 495 nm, emission 530 nm, Invit-
rogen, Tokyo, Japan) for 1 h, and immediately fluores-
cent compound 2 ,7 -dichlorofluorescein (DCF) was de-
tected by confocal laser microscopy (Leica-Microsystems,
Tokyo, Japan). In some experiments, the glomeruli were
pre-exposed RPMI-1640 with diphenylene iodinium (DPI,
100 µM), allopurinol (Allo, 1 mM), N(G)-nitro-L-arginine
meth ylester(L-N AME,1mM)or4,4  -diisothiocyano-2,2 -
stilbenedisulfonic acid (DIDS, 100 µM) before the ex-
periment. The mean fluorescence intensity of the isolated
glomeruli (total 600 glomeruli from six rats in each group)
was analysed by Leica TCS-NT system software (Leica-
Microsystems).
Lucigenin chemiluminescence assay for production
of ROS in isolated glomeruli
The superoxide production in glomeruli was measured
by using lucigenin chemiluminescence as described [8].
Lucigenin chemiluminescence was expressed as units per
minute per milligram of weight (unit/min/mg).
In situ detection of NO and ROS
The production levels of NO and ROS resulting from NOS
coupling were imaged by confocal laser microscopy after
renal perfusion with DCFH-DA and diaminorhodamine-
4Macetoxymethylester(DAR-4MAM;excitation560nm,
emission 575 nm, Sekisui Medical, Tokyo, Japan) with
L-arginine as previously described [2]. The mean NO
and ROS fluorescence intensity of glomeruli (total 100
glomeruli from five rats in each group) was analysed by
Leica TCS-NT system software (Leica-Microsystems).
Western immunoblotting
Portions of the isolated glomeruli (100 µg/lane) were sub-
jected to SDS–PAGE. For immunoblot analysis of the
dimeric form of eNOS, samples were not heated and the
temperature of the gel was maintained below 10◦C dur-
ing electrophoresis (low-temperature SDS–PAGE). Anti-
eNOS antibody (Santa Cruz biotechnology, Santa Cruz,
CA, USA), anti-phospho eNOS antibody (Santa Cruz),
anti-actin antibody (Sigma), anti-3-nitrotyrosine antibody
(Abcam, Tokyo, Japan) and anti-GTP cyclohydrolase 1
(GTPCH1) antibody (Santa Cruz) were used as the primary
antibodies. Signals were detected using the ECL system
(Amersham Biosciences, Piscataway, NJ, USA).
Immunohistochemistry of nitrotyrosine
Cryostat sections (6 µm) fixed in 4% buffered
paraformaldehyde were stained with an antibody against
nitrotyrosine (Upstate, Lake Placid, NY, USA). Detection
was carried out using the DAKO EnVision+TM system and
diaminobenzidine (Dako Japan, Tokyo, Japan).
Determination of serum hydrobiopterin concentrations
Tetrahydrobiopterin (BH4) and dihydrobiopterin (BH2)
concentrations were determined by high-performance liq-
uid chromatography (HPLC) as previously described [2].
Quantitative real-time polymerase chain reaction
for GTPCH1
RNA isolation and quantitative real-time polymerase
chain reaction (qRT-PCR) were performed as previ-
ously described [2]. Primers and probes for GTPCH1
(NM_024356) are listed below: GTPCH1 forward probe,
5 -CAGATGTCCTGAACGATGCT-3 ; reverse probe,3808 M. Satoh et al.
5 -ATATGGACCCTTCCCACAAA-3 ; TaqMan probe,
5 -FAM-TCCATGTGTGAGCATCACCTGGTC-BHQ-3 .
The change in the expression was expressed by standardiz-
ing RNA levels corrected for glyceraldehyde-3-phosphate
dehydrogenase expression in the sample.
Statistical analysis
Values were expressed as mean ± SD. All parameters
were evaluated with the two-tailed unpaired Student’s
t-test, Welch’s t-test or Mann-Whitney’s U-test. A P-value
<0.05 denoted the presence of a statistically significant
difference.
Results
Effects of losartan on renal function in diabetic rats
Table 1 summarizes the characteristics of Cont, Cont+Los,
DM and DM+Los rats. There was no difference in phys-
iological data between Cont and Cont+Los groups. At
8 weeks after STZ injection, the body weight of di-
abetic rats was significantly lower and glucose levels
higher compared with the control rats (P < 0.05). Ad-
ministration of losartan resulted in a slight but not sig-
nificant decrease in MAP. There were no differences in
serum creatinine levels between the groups. Urinary al-
bumin excretion was increased significantly in DM rat
(0.06 ± 0.02 versus 0.89 ± 0.19 mg/day, respectively,
P < 0.05) and losartan treatment significantly decreased
the level of albuminuria (0.48 ± 0.25 mg/day, P < 0.05
versus DM).
Effects of losartan on ROS generation in diabetic
nephropathy
ROS production in isolated glomeruli was evaluated by
DCFH conversion to DCF and imaged by confocal laser-
scanning microscopy. DCF fluorescence was strong, indi-
cating superoxide production, in the isolated glomeruli of
diabeticratscomparedwiththoseofcontrolrats(Figure1A;
4.0 ± 0.6 fold, P < 0.05 versus Cont). The DCF flu-
orescence was blocked when the glomeruli were incu-
bated in the presence of the superoxide scavenger Tiron,
confirming that the signal originated from superoxide
(data not shown). The fluorescence intensity in the iso-
lated glomeruli from losartan-treated DM rats was sig-
nificantly reduced (Figure 1A; 1.8 ± 0.5 fold, P < 0.05
versus DM).
Mechanism of ROS production in diabetic nephropathy
Glomerular ROS generation in DM was blocked by
NAD(P)H oxidase inhibitor, DPI and NOS inhibitor and
L-NAME (Figure 1B; 2.0 ± 0.6 fold and 2.6 ± 0.4 fold,
respectively, P < 0.05 versus DM). However, pretreatment
with mitochondrial anion channel inhibitor, DIDS and xan-
thine oxidase inhibitor, Allo had no effects (data are not
shown). These results suggest that ROS production in the
isolated glomeruli of DM rats was mediated via NAD(P)H
oxidase and NOS activation, but not via a xanthine oxidase
or mitochondrial pathway.
Effects of losartan NAD(P)H oxidase activity in diabetic
nephropathy
ROSproductionbyNAD(P)Hoxidaseinisolatedglomeruli
was determined by lucigenin chemiluminescence assay
(Figure 1C). ROS production by NAD(P)H oxidase was
significantly increased in DM rats compared with Cont rats
(411 ± 80 versus 205 ± 33 RLU/min/mg tissue, respec-
tively, P < 0.05) and losartan treatment attenuated ROS
production (297 ± 52 RLU/min/mg tissue, P <0.05 versus
DM).
Effect of losartan on NO and ROS production in diabetic
nephropathy
Figure 2 shows ROS and NO imaging in control and dia-
beticglomerulitreatedwithorwithoutlosartan.Generation
of ROS and NO in the glomeruli were evaluated by the flu-
orescent intensity of DCF and DAR-4M, respectively. NO,
but not ROS, was detected in the glomeruli of the Cont
rats. However, bioavailable NO was decreased and ROS
production was increased in the glomeruli of DM rats com-
pared with the Cont rats (1.5 ± 0.3 fold and 4.4 ± 0.3
fold, respectively, P < 0.05 versus Cont). Losartan treat-
ment significantly increased NO production and decreased
ROS production in the glomeruli of DM (0.2 ± 0.1 fold
and 2.7 ± 0.3 fold, respectively, P < 0.05 versus DM).
Theseresultssuggestthattreatmentofdiabeticnephropathy
with losartan normalized the imbalance of NO/ROS in the
glomeruli.
Effects of losartan on eNOS dimerization in diabetic
nephropathy
The eNOS protein dimer/monomer ratio was decreased in
the glomeruli of DM rats compared with those of Cont rats
(Figure 3; 2.0 ± 1.0 and 9.7 ± 1.1, respectively, P < 0.05
versus Cont). However, losartan treatment prevented the
decrease of the ratio in the diabetic glomeruli (9.4 ± 1.1,
P < 0.05 versus DM). Losartan treatment did not influence
the eNOS phosphorylation in the glomeruli of DM.
Effects of losartan on protein nitrosification in diabetic
nephropathy
Bioavailable NO is decreased by reacting with superox-
ide to form peroxynitrite. Generation of peroxynitrite in
diabetic glomeruli, especially in endothelial cells, was con-
firmed by immunohistochemistry using the nitrotyrosine
antibody (Figure 4A). Losartan treatment decreased ni-
trotyrosine staining in glomeruli. The elevated level of
nitrotyrosine in isolated glomeruli from DM rats was
also confirmed (Figure 4B; 2.5 ± 0.6 fold, P < 0.05
versus Cont), and the elevation was completely inhib-
ited by losartan treatment (1.6 ± 0.3 fold, P < 0.05
versus DM).ARB ameliorates ROS and NO imbalance 3809
Table 1. Physiological data
Control DM
Group No treatment Losartan No treatment Losartan
Number 11 11 11 11
Body weight (g) 401 ± 12 421 ± 18 355 ± 23a 338 ± 12b
Blood glucose (mg/dl) 127 ± 7 121 ± 9 499 ± 50a 448 ± 76b
Mean blood pressure (mmHg) 94 ± 59 2 ± 5 104 ± 79 8 ± 5
Urinary albumin excretion (mg/day) 0.06 ± 0.02 0.08 ± 0.03 0.89 ± 0.19a 0.48 ± 0.25b,c
Serum creatinine (mg/dl) 0.30 ± 0.02 0.31 ± 0.03 0.28 ± 0.05 0.31 ± 0.04
Data are mean ± SD.
aP < 0.05 versus control + no treatment.
bP < 0.05 versus control + losartan.
cP < 0.05 versus DM + no treatment.
Fig. 1. Superoxide production and pathway in diabetic glomeruli. (A) Isolated glomeruli of control with no treatment rats (Cont), diabetic rats (DM)
and losartan-treated diabetic rats (DM+Los) were incubated with 2 ,7 -dichlorofluorescein diacetate (DCFH) and superoxide production was measured
(Bar = 100 µm). Relative intensity was quantified. Data are shown relative to the Cont. Data are mean ± SD of 100 glomeruli from six rats in each
group(total600glomeruli).Los;losartantreatment. ∗P<0.05versusCont, †P<0.05versusDM+notreatment.(B)GlomeruliofDMwereseparately
incubated with substrates of various enzymes and superoxide production was measured by DCFH staining (Bar = 100 µm). Relative intensity was
quantified. Data are shown relative to the Cont. Data are mean ± SD of 100 glomeruli from six Cont or DM rats in each group (total 600 glomeruli).
DPI, diphenylene iodonium; L-NAME, N(G)-nitro-L-arginine methyl ester. ∗P < 0.05 versus Cont, †P < 0.05 versus DM (−). (C) The superoxide
production in glomeruli was measured by lucigenin chemiluminescence. Extracted protein from Cont, Cont+Los, DM and DM+Los glomeruli were
used. Data are mean ± SD of six rats in each group. ∗P < 0.05 versus Cont, †P < 0.05 versus DM + no treatment.3810 M. Satoh et al.
Fig. 2. In situ detection of nitrate oxide (NO) and reactive oxygen species (ROS). Representative images of NO (top) and ROS (bottom) in renal cortex
of control rats (Cont), diabetic rats (DM) and DM rats treated with losartan (DM+Los). Upper NO and lower ROS images are the same region of renal
cortex. Arrowhead indicates glomerulus. Generation of ROS and NO was evaluated by the fluorescent intensity of DCF and DAR-4M, respectively
(Bar = 100 µm). Data are mean ± SD of 20 glomeruli from five rats in each group (total 100 glomeruli). ∗P < 0.05 versus Cont, †P < 0.05 versus DM
+ no treatment.
Fig. 3. Western blot analysis for eNOS in the glomeruli. Represen-
tative blots of eNOS after low-temperature sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and phosphorylated (phospho)-eNOS.
Theintensityofdimers,monomerseNOS,phospho-eNOSandtotaleNOS
was determined by NIH Image software, and the results are expressed as
the dimer/monomer ratio and phospho-eNOS/total eNOS ratio. Data are
mean ± SD of six rats in each group. ∗P < 0.05 versus Cont, †P < 0.05
versus DM.
Serum tetrahydrobiopterin levels in diabetic rats
BH4 is an essential cofactor of NOS. ROS such as per-
oxynitrite or nitrogen dioxide convert BH4 into BH2, and
BH4 deficiency decreases NO bioactivity. Serum BH4 and
BH2 levels were measured by HPLC. The BH4 levels were
decreased in DM rats compared with Cont rats (Figure 5A;
2.0 ± 0.7 and 4.5 ± 0.6 ng/ml, respectively, P < 0.05 ver-
sus Cont), and losartan treatment increased the levels in
rats with diabetic nephropathy (3.6 ± 0.6 ng/ml, P < 0.05
versus DM). In contrast, the BH2 levels were increased in
DMratscomparedwithContrats(Figure5A;4.8±0.5and
1.2 ± 0.9 ng/ml, respectively, P < 0.05 versus Cont) and
losartan treatment decreased the levels in rats with diabetic
nephropathy (2.2 ± 0.6 ng/ml, P < 0.05 versus DM).
The key enzyme involved in de novo BH4 synthesis is
GTPCH1. The GTPCH1 mRNA expression in glomeruli
was not changed in the DM group compared to the Cont
group (Figure 5B; 1.15 ± 0.15 fold). Losartan treatment
also showed no changes in GTPCH1 expression in DM
glomeruli (0.88 ± 0.14 fold, P < 0.05 versus DM). How-
ever, the protein expression was significantly decreased in
DMandlosartanrestoredproteinexpression(Figure5C;0.4
± 0.1 fold and 1.2 ± 0.2 fold, respectively). These results
suggest that GTPCH1 was decreased in the protein levelARB ameliorates ROS and NO imbalance 3811
Fig. 4. Nitrotyrosine formation in the glomeruli. (A) Immunohistochem-
istry of nitrotyrosine in control rats (Cont), diabetic rats (DM) and DM
rats treated with losartan (DM+Los) (Bar = 100 µm). (B) Representative
blots of nitrotyrosine. The intensity of the 55 kDa band was determined by
NIH Image software, and the results are expressed as relative to the Cont.
Data are mean ± SD of six rats in each group. ∗P < 0.05 versus Cont, †P
< 0.05 versus DM.
Fig. 5. Serum biopterin concentration and glomerular GTPCH1 expres-
sion. (A) Serum levels of tetrahydrobiopterin (BH4) and dihydrobiopterin
(BH2) in control rats (Cont), diabetic rats (DM) and DM rats treated with
losartan (DM+Los) were determined using HPLC. Data are mean ± SD
ofsixratsineachgroup. ∗P<0.05versusCont, †P<0.05versusDM.(B)
Glomerular mRNA expression of GTPCH1 in Cont, DM and DM+Los.
(C) Glomerular protein expression of GTPCH1 in Cont, DM and
DM+Los. Representative blots of GTPCH1 are shown. Data are mean
± SD of six rats in each group. ∗P < 0.05 versus Cont, †P < 0.05 versus
DM.
in the isolated glomeruli of DM rats and losartan restored
GTPCH1 protein levels and kept serum BH4.
Discussion
In the present study, we explored whether losartan im-
proves NO production in the glomeruli of rats with diabetic
nephropathy independent of the blood pressure lowering
effects. Our data demonstrated that blockade of Ang II
signalling in diabetic glomeruli reduced ROS production
and improved the eNOS coupling statement, and indeed
restored NO bioavailability in glomeruli.
In the present study, we used an STZ-induced type 1
diabetes model to demonstrate the therapeutic efficacy of
losartan on glomerular eNOS uncoupling in early diabetic
nephropathy.Butsomeofthecharacteristicearlyalterations
in human diabetic nephropathy such as increased albumin-
uria, the development of glomerular hyperfiltration and
some of the characteristic histopathological changes can
be observed in the STZ-induced diabetic model [9]. More-
over, studies in the STZ-induced diabetic rat model have
shown increased renal oxidative stress induced by hyper-
glycaemia [10,11]. So we have used this model for the
studyofglomerularendothelial dysfunctioninducedbyhy-
perglycaemia [2,12]. In the present study, we also used this
STZmodelfortheinvestigationofhyperglycaemia-induced
eNOS uncoupling and the effects of losartan.
It has been reported that ARB have anti-oxidative effects
inhumanessentialhypertension[13],hypertensivediabetic
nephropathy [14] and mouse type 2 diabetic nephropathy
[15].DataofthepresentstudyalsoindicatedthatARBtreat-
ment suppressed ROS production in diabetic glomeruli. It
is known that Ang II mediates ROS generation through
activation of NAD(P)H oxidase [16]. As we reported previ-
ously[2],activationofNAD(P)Hoxidaseisalsoinvolvedin
ROS production in the diabetic glomeruli. We confirmed
by direct observation that ARB reduced ROS production
through the reduction of NAD(P)H oxidase activity. These
finding are consistent with the previous reports that ARB
attenuated NAD(P)H oxidase-dependent ROS production
[17].
In addition, using two different methods, we confirmed
uncoupled eNOS in diabetic glomeruli. ARB improved the
eNOS coupling state in diabetic glomeruli and recovered
NO production to normal levels. The uncoupled NOS in
diabetic glomeruli was confirmed by the decrease of eNOS
dimer form and by in situ NO imaging. The in situ NO
imaging method is useful for detecting NOS dysfunction.
We used a kidney perfusate containing L-arginine and Ca2+
to enhance NO production. Under normal conditions, cou-
pled NOS converts L-arginine into L-citrulline and pro-
ducesNO.However,whenNOScofactorBH4isatsubopti-
mal concentrations, L-arginine produces superoxide rather
than NO through uncoupled NOS [18]. This ROS produc-
tion could be detected by the ROS fluorescent indicator,
DCFH, in our in situ imaging method. Administration of
ARB improved NOS function, as determined by increased
glomerular NO production and decreased glomeru-
lar ROS production. These results also suggest that3812 M. Satoh et al.
ARB can improve uncoupled NOS in the diabetic
glomeruli.
BH4 serves as a critical co-factor for eNOS and de-
ficiency of BH4 results in eNOS uncoupling, which is
associated with increased superoxide and decreased NO
production. We found that serum levels of BH4 in the di-
abetic rats were lower than those in control rats, and ARB
restored BH4 bioavailability in diabetic nephropathy by re-
duced catabolism for oxidation to BH2. The reduced BH4
oxidation by ARB leads to eNOS recoupling and results
in increased NO and reduced ROS production by the en-
zyme. BH4 bioavailability is potently influenced by oxida-
tive stress, by the downregulation of GTPCH1 [19] and by
oxidation to inactive BH2 [20]. Recently, Chalupsky et al.
[21] demonstrated the role of dihydrofolate reductase in the
regulation of BH4 and NO bioavailability in the endothe-
lium.Endothelial NAD(P)Hoxidase-derived hydrogen per-
oxide downregulated dihydrofolate reductase expression in
response to angiotensin II, resulting in BH4 deficiency and
uncouplingofeNOS.Moreover,Xuetal.[22]demonstrated
that diabetic hyperglycaemia activates the 26S proteasome
viaperoxynitriteandresultsintheubiquitinationanddegra-
dation of GTPCH1, which is the rate-limiting enzyme for
BH4 de novo synthesis. We confirmed that nitrotyrosine
formation, peroxynitrite indicator, was elevated in diabetic
glomeruli and attenuated by losartan treatment. Moreover,
we confirmed that GTPCH1 protein expression levels were
decreased in diabetic glomeruli and attenuated by losar-
tan treatment without affecting mRNA expression, so it
may influence the GTPCH1 activity. As a result, losartan
may improve eNOS uncoupling in STZ-induced diabetic-
glomeruli.
On the other hand, statins are reported to potentiate GT-
PCH1 gene expression and BH4 synthesis, thereby improv-
ing eNOS function [23]. Administration of the calcium
channel blocker, benidipine, is also reported to be effec-
tive in preventing BH4 deficiency by activating GTPCH1
in type II diabetic rats [24]. GTPCH1 is also subject to
posttranslational modification by phosphorylation. In rat
mesangial cells, Ang II and platelet-derived growth factor
are reported to increase GTPCH1 activity by phosphory-
lation via a protein kinase C-dependent mechanism [25].
However, the role of GTPCH1 phosphorylation in ECs has
not been determined.
The 2-week ARB treatment did not cause significant
pathological changes in the kidneys of STZ rats. However,
ARB treatment resulted in a significant reduction of albu-
minuria. It is possible that this effect is the result of im-
provement of endothelial function. Improvement of eNOS
uncoupling including BH4 by ARB treatment leads to in-
creased NO viability and maintenance of endothelial func-
tion; then ARB would reduce microalbuminuria in STZ
rat. Recently, the usefulness of microalbuminuria in pre-
dicting increased risk of cardiovascular and renal diseases
is well established in diabetic patients, as well as in es-
sential hypertensive patients and in the general population
[26]. Thus, the reduction of microalbuminuria could then
bearelevanttherapeuticstrategyforreducingorpreventing
cardiovasculareventsinpatientswithdiabetesandessential
hypertension.
Changes of NO production have been associated with
glomerular hyperfiltration, vascular permeability [27].
ARB including losartan can induce glomerular haemody-
namics improvement by reducing efferent artery resistance
[28]. So losartan may improve the eNOS–BH4 coupling
by improving glomerular hyperfiltration and/or endothelial
function. In renal diseases, glomerular haemodynamic im-
provement reduces oxidative stress. We have demonstrated
that, in a subtotal nephrectomized rats model that shows in-
creased glomerular hyperfiltration, glomerular superoxide
productionwasincreasedandARBamelioratedsuperoxide
production by attenuating NAD(P)H oxidase activity [29].
On the other hand, in aorta of the rat STZ model, ARB has
been reported to improve eNOS uncoupling by inhibiting
NAD(P)H oxidase activity, so losartan may improve eNOS
uncoupling by direct action to the glomerular endothelium.
So, losartan may demonstrate its anti-oxidative effects by
both reducing glomerular hypertension and direct endothe-
lial protection.
In conclusion, we have demonstrated in the present
study that the imbalance between NO and ROS contributes
to renal dysfunction in diabetic nephropathy. ARB im-
proved eNOS uncoupling by increasing serum BH4 level,
which contributed to the reduction in diabetic glomeru-
lar ROS production. These mechanisms add a new di-
mension to the renoprotective effects of ARB in diabetic
nephropathy.
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